Systemic lupus erythematosus (SLE) is a heterogenous disease, and therapies are used to prevent flares, preserve organ function, and manage comorbidities. In recent years, new drugs, including belimumab and anifrolumab, have shown some success in disease control in this patient population. However, clinical trials have yet to answer how best to identify the right patient to treat with biologic therapy and when to start medication.
Rheumatologist Dr Anca Askanase from Columbia University Medical Center is joined by her friend and colleague Dr Joan Merrill from the University of Oklahoma Health Sciences Center to discuss optimal treatments for patients with active SLE, including European Alliance of Associations for Rheumatology recommendations, therapeutic combination considerations, and current clinical trial data.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Optimal Treatment for Active Systemic Lupus Erythematosus - Medscape - Jan 17, 2023.
Comments